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246a Monday, February 22, 2010such as Crouzon syndrome and bladder cancer. This mutation has been shown
to stabilize the isolated TM domain dimers in lipid membranes, but it is not
known if it stabilizes the full length FGFR3 receptor dimers in the plasma mem-
brane of mammalian cells.
To address the effect of the mutation in mammalian cells, we have determined
free energies of dimerization for the wild type and mutant FGFR3 in mamma-
lian (HEK293T and CHO) plasma membranes using the QI Fo¨rster resonance
energy transfer (FRET) technique [Li et al.,2008]. The measured change in the
dimerization free energy due to the Ala391Glu mutation is 1.2 kcal/mol, con-
sistent with previous reports of hydrogen bond strength in proteins, as well as
results for the isolated FGFR3 TM domains. Thus, we have shown that the mu-
tation stabilizes the full length FGFR3 dimers in mammalian cells. We propose
that this dimer stabilization is the major cause for FGFR3 overactivation and
human pathologies.
Li E,Placone J,Merzlyakov M, Hristova K (2008) Quantitative measurements
of protein interactions in a crowded cellular environment.Anal Chem
80:5976-5985.
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Fibroblast growth factor receptor 3 (FGFR3) is a receptor tyrosine kinase which
plays an important role in long bone development. The Gly380Arg mutation in
FGFR3 transmembrane domain has been linked to achondroplasia, the most
common form of human dwarfism. However, the exact mechanism underlying
the pathology is under debate. One hypothesis is that the mutation stabilizes the
active FGFR3 dimer in the plasma membrane. To test this hypothesis, here we
measure the activation of wild type and mutant FGFR3 in mammalian cells,
and analyze the activation using a physical-chemical model accounting for di-
merization, ligand binding and phosphorylation probabilities. Our results dem-
onstrate that the achondroplasia mutation does not increase the dimerization
propensity of FGFR3. Instead, the data suggest that the mutation induces
a structural change in the unliganded dimer. We propose that this structural
change is a cause for pathogenesis in achondroplasia.
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Ca2þ cycling through the SR in muscle cells is largely controlled by the Ca-
pump (SERCA). SERCA transports Ca2þ into the SR and is inhibited by phos-
pholamban (PLB) at submicromolar [Ca2þ], and this inhibition can be relieved
by adrenergic stimulation. Contraction takes place when the Ca-release channel
opens and the intracellular [Ca2þ] is high. One of the most common symptoms
of heart failure (HF) is impaired calcium handling, frequently resulting from
decreased SERCA activity. We are using EPR and NMR to study the relation-
ships among structure, dynamics, and function of PLB, with the goal of design-
ing LOF-PLB mutants (PLBM) that can compete with WT-PLB and thus relieve
SERCA inhibition. Several studies have shown that a pseudophosphorylated
PLB (S16E-PLB) is effective for gene therapy in rodents and sheep, and we
are using spectroscopic methods to refine this approach. We have developed
a system for examining the function and interactions of SERCA and PLB in
HEK cells. Active SERCA is expressed at a level high above basal ATPase ac-
tivity, and cells are co-transfected with WT-PLB and/or PLBM to measure
SERCA inhibition in living cells. Unlike S16E-PLB, these mutants are able
to respond to adrenergic stimulation. In addition to quantifying SERCA activity
in the presence of PLBM, we measure the ability of each mutant to compete
with WT-PLB for binding to SERCA. This is done by measuring fluorescence
resonance energy transfer (FRET) between labeled SERCA and WT-PLB. If
PLBM displaces WT-PLB, less energy is transferred between fluorophores
and a decrease in FRET is observed. Based on these results, rAAV is used to
test PLBM in rodent and porcine models of HF for efficacy in vivo and ability
to respond to adrenergic stimulation, with the goal of developing a novel, gene
therapy based treatment for HF.
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We discovered a low-affinity, high-capacity L-arginine (L-Arg) transport pro-
cess in rat cardiomyocytes consistent with the activity of the CAT-2A memberof the y(þ) family of cationic amino acid transporters (Peluffo, J Physiol,
580:925-936, 2007), set to function in parallel with the previously described
high-affinity, low-capacity CAT-1 (Lu et al., Biosci Rep, 29:271-281, 2009).
In assessing the role of a low-affinity transporter in this setting, we propose
that CAT-2A protects cardiac muscle cells by ensuring the availability of
proper L-Arg levels for the synthesis of nitric oxide (NO) via NO synthase
(NOS). To test this hypothesis, acutely-isolated cardiomyocytes were loaded
with the dye coelenterazine that greatly increases its fluorescence quantum
yield in the presence of peroxynitrite (ONOO ) and superoxide radicals. Cells
were then exposed to 20 or 100 mM ONOO and changes in fluorescence were
followed with a spectrofluorometer. Addition of extracellular L-Arg reduced
ONOO-induced fluorescence in a concentration-dependent manner, an effect
that was not mimicked by D-arginine or L-lysine and was fully blocked by
the NOS inhibitor L-NAME. L-Arg reduced fluorescence with Ki values of
0.84 5 0.12 and 1.26 5 0.16 mM at 20 and 100 mM ONOO , respectively.
L-Arg ‘‘zero effect’’ on ONOO-induced fluorescence was also dependent on
ONOO concentration, with values of 145 and 363 mM for 20 and 100 mM
ONOO , respectively. Below these values, decreasing concentrations of L-
Arg progressively increased ONOO-induced fluorescence, an effect that was
also blocked by L-NAME. All these effects can be explained by NOS-mediated
NO synthesis, which may turn to ONOO production at limiting L-Arg. Since
ONOO has detrimental effects on cardiac contractility, these results suggest
a cardioprotective role for the low-affinity L-Arg transporter, ensuring proper
supply of NOS substrate under a variety of physiological and pathological con-
ditions.
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Plexin family are unique transmembrane receptors protein known to regulate
several cellular processes including axonal guidance in the developing nervous
system. Upon activation, plexin initiates signaling processes, which involve
several small GTPases of the Ras and Rho families (R-Ras, Rac1, Rnd1, and
RhoD) that regulates cytoskeletal dynamics and cell adhesion. Plexins are
unique amongst transmembrane receptors because its several cytoplasmic re-
gions interact directly with small GTPases. Specifically, plexins possess a do-
main with homology to GTPase activating proteins (GAPs). As part of their ac-
tivation, plexin family shows GAP activity toward R-Ras. However, the
mechanism of activation is not known till date because of lack of information
about the structure and function of these receptor proteins. In this context, we
have studied the structure, function of intracellular region of PlexinB1 and their
binding interaction with small GTPase. The structure is monomeric and binds
to Rac1, Rnd1 as well as Rras, but not H-Ras. These findings suggest that the
monomeric form of the intracellular region is primed for GAP activity and ex-
tend a model for plexin activation.
[1] Tong, Y., et al. (2008) Structure 16, 246-258.[2] Bouguet-Bonnet, S. &
Buck, M (2008) J.Mol.Biol. 377,1474-87.[3] Tong, Y, et al. (2007) J.Biol.
Chem. 282, 37215-37224.[4] Hota, P. & Buck, M. (2009) Protein Science,
18(5):1060-71.[5] Tong, Y., et al. (2009) J. Biol. Chem. Submitted.
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TA systems have recently been linked to medically important processes such
as biofilm formation, bacterial persistence after exposure to antibiotics, and
bacterial pathogenesis. Toxin-Antitoxin (TA) systems are stable protein com-
plexes consisting of a toxin, whose action is mechanistically distinct from exo-
toxins (e.g. botulinum, anthrax or cholera toxins), in complex with an anti-
toxin, its specific inhibitor. The release of TA toxin occurs under specific
